121 related articles for article (PubMed ID: 37292782)
1. Interruption of the Intratumor CD8:Treg Crosstalk Improves the Efficacy of PD-1 Immunotherapy.
Geels SN; Moshensky A; Sousa RS; Walker BL; Singh R; Gutierrez G; Hwang M; Mempel TR; Nie Q; Othy S; Marangoni F
bioRxiv; 2023 May; ():. PubMed ID: 37292782
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating mast cells stimulate ICOS
Lv Y; Tian W; Teng Y; Wang P; Zhao Y; Li Z; Tang S; Chen W; Xie R; Lü M; Zhuang Y
J Adv Res; 2024 Mar; 57():149-162. PubMed ID: 37086778
[TBL] [Abstract][Full Text] [Related]
4. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Drerup JM; Deng Y; Pandeswara SL; Padrón ÁS; Reyes RM; Zhang X; Mendez J; Liu A; Clark CA; Chen W; Conejo-Garcia JR; Hurez V; Gupta H; Curiel TJ
Cancer Res; 2020 Nov; 80(22):5063-5075. PubMed ID: 32948605
[TBL] [Abstract][Full Text] [Related]
5. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
[TBL] [Abstract][Full Text] [Related]
7. Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models.
Scherrer D; Barrett N; Teyton L; Pearce T; Nitcheu J; Pouletty P; Santo J; Ehrlich HJ
Mol Cancer Ther; 2022 Dec; 21(12):1788-1797. PubMed ID: 36198025
[TBL] [Abstract][Full Text] [Related]
8. Tumor-associated Tregs obstruct antitumor immunity by promoting T cell dysfunction and restricting clonal diversity in tumor-infiltrating CD8+ T cells.
Noyes D; Bag A; Oseni S; Semidey-Hurtado J; Cen L; Sarnaik AA; Sondak VK; Adeegbe D
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35618289
[TBL] [Abstract][Full Text] [Related]
9. The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8
Carmenate T; Montalvo G; Lozada SL; Rodriguez Y; Ortiz Y; Díaz C; Avellanet J; Kim J; Surh CD; Graça L; León K
Front Immunol; 2022; 13():974188. PubMed ID: 36059465
[TBL] [Abstract][Full Text] [Related]
10. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Oweida A; Hararah MK; Phan A; Binder D; Bhatia S; Lennon S; Bukkapatnam S; Van Court B; Uyanga N; Darragh L; Kim HM; Raben D; Tan AC; Heasley L; Clambey E; Nemenoff R; Karam SD
Clin Cancer Res; 2018 Nov; 24(21):5368-5380. PubMed ID: 30042205
[No Abstract] [Full Text] [Related]
11. Immunotherapy Targeting CCR8+ Regulatory T Cells Induces Antitumor Effects via Dramatic Changes to the Intratumor CD8+ T Cell Profile.
Ueyama A; Nogami W; Nashiki K; Haruna M; Miwa H; Hagiwara M; Nagira M; Wada H; Nagira Y
J Immunol; 2023 Aug; 211(4):673-682. PubMed ID: 37350632
[TBL] [Abstract][Full Text] [Related]
12. Tumors establish resistance to immunotherapy by regulating T
Marshall LA; Marubayashi S; Jorapur A; Jacobson S; Zibinsky M; Robles O; Hu DX; Jackson JJ; Pookot D; Sanchez J; Brovarney M; Wadsworth A; Chian D; Wustrow D; Kassner PD; Cutler G; Wong B; Brockstedt DG; Talay O
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243932
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
14. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
16. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
[TBL] [Abstract][Full Text] [Related]
17. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8
Moreno Ayala MA; Campbell TF; Zhang C; Dahan N; Bockman A; Prakash V; Feng L; Sher T; DuPage M
Immunity; 2023 Jul; 56(7):1613-1630.e5. PubMed ID: 37392735
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PCSK9 enhances the antitumor effect of PD-1 inhibitor in colorectal cancer by promoting the infiltration of CD8
Wang R; Liu H; He P; An D; Guo X; Zhang X; Feng M
Front Immunol; 2022; 13():947756. PubMed ID: 36003387
[TBL] [Abstract][Full Text] [Related]
19. IL-21 Is an Accomplice of PD-L1 in the Induction of PD-1-Dependent Treg Generation in Head and Neck Cancer.
Zhao Y; Zhang Z; Lei W; Wei Y; Ma R; Wen Y; Wei F; Fan J; Xu Y; Chen L; Lyu K; Lin H; Wen W; Sun W
Front Oncol; 2021; 11():648293. PubMed ID: 34026621
[TBL] [Abstract][Full Text] [Related]
20. PD-L1-Independent Mechanisms Control the Resistance of Melanoma to CD4
Goding SR; Wilson KA; Rosinsky C; Antony PA
J Immunol; 2018 May; 200(9):3304-3311. PubMed ID: 29602773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
